[NBIX] Neurocrine Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 39.65 Change: 0.61 (1.56%)
Ext. hours: Change: 0 (0%)

chart NBIX

Refresh chart

Strongest Trends Summary For NBIX

NBIX is in the medium-term down -8% below S&P in 1 month and down -30% below S&P in 7 months and down -30% in 7 months. In the long-term up 58% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Neurocrine Biosciences, Inc. discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It develops drugs for endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. The company?s products in clinical development stage include Elagolix, a Phase III drug for endometriosis; Vesicular Monoamine Transporter 2 Inhibitor (VMAT2), a Phase II drug for movement disorders; CRF1 Antagonist, a Phase II drug for stress-related disorders; and Elagolix, a Phase II drug for uterine fibroids. Its research programs comprise G Protein-Coupled Receptor 119 (GPR119) for type II diabetes; VMAT2 for tourette syndrome schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men?s and women?s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other con

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-11.83% ROE-12.96% ROI
Current Ratio22.19 Quick Ratio Long Term Debt/Equity Debt Ratio0.04
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities275.28 M Cash From Investing Activities-170.01 M Cash From Operating Activities-4.22 M Gross Profit
Net Profit-23.99 M Operating Profit-25.32 M Total Assets511.2 M Total Current Assets389.42 M
Total Current Liabilities17.55 M Total Debt560 K Total Liabilities44.27 M Total Revenue
Technical Data
High 52 week125.85 Low 52 week68.32 Last close80.95 Last change2.59%
RSI33.79 Average true range3.03 Beta1.39 Volume828.99 K
Simple moving average 20 days-3.81% Simple moving average 50 days0.07% Simple moving average 200 days-18.61%
Performance Data
Performance Week-4% Performance Month-9.04% Performance Quart-8.52% Performance Half-30.58%
Performance Year-5.23% Performance Year-to-date13.36% Volatility daily2.34% Volatility weekly5.23%
Volatility monthly10.72% Volatility yearly37.14% Relative Volume252.57% Average Volume1.21 M
New High New Low

News

2019-03-23 10:02:00 | 2 Biotech Takeout Targets Perfect for Biogen

2019-03-20 10:43:28 | Sage Stock Pops on FDA Approval for Postpartum Depression Drug

2019-03-15 09:30:01 | CTLT or NBIX: Which Is the Better Value Stock Right Now?

2019-03-12 08:00:00 | Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia

2019-03-07 09:15:02 | Stocks Slide for Third Straight Day

2019-03-05 16:01:00 | Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

2019-03-05 08:01:53 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-03-01 12:33:17 | Why These 2 Biotech Stocks Might Be Next On The Takeover List

2019-02-28 11:56:07 | Why Neurocrine Biosciences, Inc. NASDAQ:NBIX Is An Attractive Investment To Consider

2019-02-22 11:31:07 | Voyager Therapeutics stock jumps on 2nd Parkinson's deal

2019-02-12 09:30:02 | CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?

2019-02-08 08:05:10 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-02-08 06:48:43 | Neurocrine Biosciences Inc NBIX Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-06 21:20:54 | Edited Transcript of NBIX earnings conference call or presentation 5-Feb-19 9:30pm GMT

2019-02-06 08:23:47 | The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

2019-02-05 20:04:56 | Neurocrine Biosciences Inc NBIX Q4 2018 Earnings Conference Call Transcript

2019-02-05 18:35:11 | Neurocrine Biosciences NBIX Beats Q4 Earnings Estimates

2019-02-05 17:37:35 | Neurocrine: 4Q Earnings Snapshot

2019-02-05 16:01:00 | Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results

2019-02-05 14:30:00 | Neurocrine Biosciences, Inc. to Host Earnings Call

2019-02-05 07:47:21 | The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

2019-01-31 14:45:22 | Here are Boston-area biotechs pursuing Parkinson's treatments

2019-01-29 13:42:25 | Here's Why Voyager Therapeutics Stock Soared as Much as 62.9% Today

2019-01-29 12:36:57 | Why Is Voyager Therapeutics Soaring Today?

2019-01-29 10:31:03 | Neurocrine Biosciences NBIX Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2019-01-29 08:02:24 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-01-29 07:00:00 | Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia

2019-01-28 09:33:02 | Will Neurocrine Biosciences Continue to Surge Higher?

2019-01-25 07:45:00 | Analysis: Positioning to Benefit within Neurocrine Biosciences, CONMED, TripAdvisor, Ryder System, Nordstrom, and Express — Research Highlights Growth, Revenue, and Consolidated Results

2019-01-16 16:01:00 | New INGREZZA® valbenazine Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders

2019-01-16 06:57:11 | 4 Defensive Stocks to Buy Amid Shutdown and Brexit

2019-01-15 16:48:00 | Here’s your guide to the upcoming biotechnology takeover wave

2019-01-15 16:01:00 | Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2018 Financial Results

2019-01-14 08:00:00 | Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences

2019-01-11 16:25:40 | Biotech Stocks Are Enjoying Their Best-Ever Start to the Year

2019-01-11 13:32:26 | Is Neurocrine Biosciences, Inc.’s NASDAQ:NBIX CEO Overpaid Relative To Its Peers?

2019-01-10 12:07:29 | 5 Biotech Stocks That Could Face M&A Next!

2019-01-09 08:05:22 | See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.

2019-01-08 08:15:37 | Why Neurocrine Biosciences Stock Rose 9.6% Yesterday

2019-01-07 12:42:05 | Neurocrine Gives Ingrezza Sales View, Updates on Pipeline

2019-01-07 07:15:46 | Neurocrine Biosciences Is a Pharma Stock to Watch

2019-01-07 06:50:00 | Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Loxo Oncology

2019-01-06 18:30:00 | Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones

2019-01-06 10:56:42 | Neurocrine Biosciences Looks Oversold

2019-01-02 16:01:00 | Neurocrine Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-31 07:51:00 | 4 of the Fastest Growing Biotech Stocks in 2019

2018-12-14 08:37:01 | Do Options Traders Know Something About Neurocrine Biosciences NBIX Stock We Don't?

2018-12-13 06:55:00 | Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Synergy Pharmaceuticals

2018-12-12 16:35:00 | Why Under Armour, Neurocrine Biosciences, and XPO Logistics Slumped Today

2018-12-12 12:49:00 | Why Neurocrine Biosciences Is Tanking